Literature DB >> 26813435

[Analysis of liver cancer incidence and trend in China].

Tingting Zuo1, Rongshou Zheng1, Hongmei Zeng1, Siwei Zhang1, Wanqing Chen2.   

Abstract

OBJECTIVE: The national population-based cancer registration data were used to analyze the liver cancer incidence and trend in China, in order to provide advise for making further strategy on liver cancer prevention and control.
METHODS: Liver cancer data of 2011 were retrieved from the database of the National Cancer Registry. The incident cases of liver cancer were estimated using age-specific rate by urban or rural areas and gender according to the national population in 2011. Liver cancer incidence data from 22 cancer registries were used to analyze the incidence trend during 2000-2011.
RESULTS: The estimates of new cases of liver cancer were about 356 thousand in China in 2011. The incidence rate was 26.39/10(5,) and the age-standardized incidence rates by Chinese standard population and by world population were 19.48/10(5) and 19.10/10(5,) respectively.There was an increasing trend of incidence rate of liver cancer in China during 2000-2011 with an average annual percentage change(AAPC) of 1.0% (95%CI: 0.5%-1.4%), 1.2% (95%CI: 0.7%-1.8%)in urban areas and 1.1% (95%CI: 0.5%-1.8%) in rural areas. After age standardization, the incidence rate was significantly decreased, with an AAPC of -1.8% (95%CI: -2.4% to -1.2%), -1.6% (95%CI: -2.2% to -0.9%) in urban and -1.4% (95%CI: -2.5% to -0.3%) in rural areas.
CONCLUSIONS: Liver cancer is a common cancer in China. As changing in people's dietary habits and implementing neonatal HBV vaccination for years, the exposure to risk factors is reducing, and age-standardized incidence rate is decreasing. While cardinal number of population is big and aging population is growing rapidly in the country, trend of incidence rate is increasing, and the burden of liver cancer is still high in China.

Entities:  

Mesh:

Year:  2015        PMID: 26813435

Source DB:  PubMed          Journal:  Zhonghua Zhong Liu Za Zhi        ISSN: 0253-3766


  7 in total

1.  Effects and mechanism of Lanthanum Citrate on the proliferation and apoptosis of hepatocellular carcinoma cell line SMMC-7721.

Authors:  Bin Chen; Zeming Hu; Biao Chen; Bofei Li
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

2.  Prognostic gene biomarker identification in liver cancer by data mining.

Authors:  Gang Liu; Haitao Tang; Chen Li; Haiyan Zhen; Zhigang Zhang; Yongzhong Sha
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

3.  Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression.

Authors:  Jisan Sun; Wentao Jiang; Dazhi Tian; Qingjun Guo; Zhongyang Shen
Journal:  Onco Targets Ther       Date:  2018-11-21       Impact factor: 4.147

4.  Epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) suppressed the growth of hepatocellular carcinoma cells by promoting Semaphorin 3B(SEMA3B).

Authors:  Jiangfeng Hu; Bensong Duan; Weiliang Jiang; Sengwang Fu; Hengjun Gao; Lungen Lu
Journal:  Cancer Med       Date:  2019-04-11       Impact factor: 4.452

5.  Spatiotemporal Trends in the Incidence of Gastrointestinal Neoplasms in Wuwei City of Northwestern China From 1995 to 2016: A Hospital-Based Retrospective Observational Study.

Authors:  Kun Liu; Shuxuan Song; Ting Fu; Yiwen Liu; Hui Zhang; Min Yan; Zhen He; Weilu Zhang; Haixia Su; Zhao Li; Zhaohua Ji; Zhongjun Shao
Journal:  Front Oncol       Date:  2021-09-03       Impact factor: 6.244

6.  Decreased DC-SIGNR expression in hepatocellular carcinoma predicts poor patient prognosis.

Authors:  Hai-Bing Xia; Hui-Ju Wang; Shu-Shu Song; Jun-Gang Zhang; Xiang-Lei He; Zhi-Ming Hu; Cheng-Wu Zhang; Dong-Sheng Huang; Xiao-Zhou Mou
Journal:  Oncol Lett       Date:  2019-11-11       Impact factor: 2.967

7.  Fasting Blood Glucose, Cholesterol, and Risk of Primary Liver Cancer: The Kailuan Study.

Authors:  Xiangming Ma; Haozhe Cui; Miaomiao Sun; Qian Liu; Xining Liu; Guangjian Li; Yaochen Wei; Qingjiang Fu; Siqing Liu; Liying Cao
Journal:  Cancer Res Treat       Date:  2021-01-19       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.